Postoperative Outcomes of the Largest HeartMate-II Experience in Turkey


ERTUGAY S. , ENGİN Ç. , NALBANTGİL S. , Kocabas S. , BALCIOGLU O., ENGIN Y., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.47, ss.1499-1502, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Introduction. HeartMate II (HMII; Thoratec Corporation, Pleasanton, Calif, United States) is a continuous-flow pump approved by the Food and Drug Administration (FDA) for bridge-to-transplantation (BIT) since 2008 and for destination therapy (DT) since 2010. Herein, we present the postoperative outcomes of HMII implantation due to end-stage heart failure in our center.